Logo
Subscribe Now

All Posts by Date

Amgen's Repatha (evolocumab) Receives the US FDA's Approval for the Treatment of Heterozygous Familial Hypercholesterolemia

Amgen's Repatha (evolocumab) Receives the US FDA's Approval for the Treatment of Heterozygous Familial Hypercholesterolemia

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Takeda's Alofisel (darvadstrocel) Receives MHLW's Approval for the Treatment of Complex Perianal Fistulas with Non-active or Mildly Active Luminal CD

Takeda's Alofisel (darvadstrocel) Receives MHLW's Approval for the Treatment of Complex Perianal Fistulas with Non-active or Mildly Active Luminal CD

Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases

Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases

Image

Stay Connected

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2021 PharmaShots - All Rights Reserved.